Dolby Laboratories, INC

Dolby Laboratories announced its third quarter fiscal 2026 financial results, reporting a decrease in revenue and net income compared to the prior year, but also declared a dividend and increased its share repurchase authorization.

Dolby Laboratories, Inc. stockholders re-elected eight directors, approved executive compensation, and ratified KPMG LLP as auditor at their 2026 Annual Meeting.

Dolby Laboratories announced its first quarter fiscal 2026 financial results, reporting a slight revenue decrease but strong momentum in Dolby Atmos and Vision, alongside a $0.36 per share cash dividend.

Dolby Laboratories announced its financial results for the fourth quarter and fiscal year 2025, reporting increased full-year revenue and cash flow from operations, alongside a cash dividend declaration.

Dolby Laboratories' Compensation Committee adopted the 2026 Executive Bonus Plan, linking executive compensation to financial performance metrics.

Dolby Laboratories announced robust third-quarter fiscal 2025 financial results, driven by increased revenue and net income, alongside continued expansion of its immersive audio and video technologies across diverse markets.

Dolby Laboratories reported a decrease in revenue for the fiscal quarter ended June 26, 2026, with licensing revenue down 3% and products and services revenue down 12%, though gross profit and net income remained robust.

Dolby Laboratories reported Q2 2026 revenue of $395.6 million, driven by licensing growth and continued adoption of Dolby Atmos and Dolby Vision.

Dolby Laboratories reports a 3% decline in Q1 fiscal 2026 revenue and a 21% drop in net income, while advancing strategic initiatives in mobile, automotive, and new platforms.

Dolby Laboratories announced a significant increase in revenue and net income for the third fiscal quarter of 2025, primarily driven by robust licensing performance across its branded technologies and patent portfolios.

Dolby Laboratories' Q2 2025 results show a slight increase in total revenue, driven by licensing, with strategic restructuring actions underway.

Dolby Laboratories' Q1 2025 results show increased revenue driven by licensing, particularly in mobile and automotive sectors, alongside strategic restructuring efforts.

Dolby Laboratories, Inc. reported a 5.9% increase in total revenue to $1.35 billion for fiscal year 2025, driven by licensing growth, despite a 2.6% decrease in net income and increased restructuring charges.

Dolby Laboratories' 2024 annual report highlights a robust licensing business, accounting for 93% of total revenue, while navigating evolving consumer trends and macroeconomic challenges.

Shriram Revankar, SVP, Advanced Technology Group of Dolby Laboratories, Inc., sold 3,000 shares of common stock on August 14, 2026 for $62.71 per share.

Ryan Nicholson, VP, CAO and Corp. Controller of Dolby Laboratories, Inc., sold 357 shares of common stock on August 4, 2026 for $60.63 per share.

John D Couling, SVP, Entertainment of Dolby Laboratories, Inc., sold 7,667 shares of common stock on August 3, 2026.

Dolby Laboratories SVP John Couling reported transactions involving Class A Common Stock, including the acquisition of shares under an employee stock option and the sale of shares.

John D. Couling, SVP of Entertainment at Dolby Laboratories, Inc., reported transactions involving Class A Common Stock, including acquisitions and dispositions, executed under a Rule 10b5-1 trading plan.

Dolby Laboratories SVP and Chief Marketing Officer Todd Pendleton sold 11,876 shares of Class A common stock on May 22, 2026.

Dolby Laboratories, Inc. announces its 2026 Annual Meeting of Shareholders, outlining proposals for director elections, executive compensation, and auditor ratification.

Dolby Laboratories announces its 2026 Annual Meeting, detailing director elections, executive compensation, and fiscal 2025 financial highlights including revenue growth and a dividend increase.

Dolby Laboratories has scheduled its 2025 Annual Meeting for February 4, 2025, and is urging shareholders to vote on key proposals, including the election of directors and executive compensation.

Dolby Laboratories has announced its 2025 Annual Meeting of Stockholders, scheduled for February 4, 2025, and is seeking approval for several key proposals, including an amendment to provide for officer exculpation.

Dagmar Dolby and related trusts decreased their beneficial ownership in Dolby Laboratories, Inc. by over one percent primarily due to charitable gifting.

Dagmar Dolby and associated family trusts have filed an amended Schedule 13D, disclosing a decrease of over one percent in their beneficial ownership of Dolby Laboratories, Inc. Class A Common Stock due to charitable and planning-related gifting.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 10.0% of Dolby Laboratories, Inc.'s Class A Stock as of May 31, 2026.

Morgan Stanley and Atlanta Capital Management Company, LLC have filed a Schedule 13G, reporting beneficial ownership of Dolby Laboratories, Inc. Class A Common Stock.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.24% beneficial ownership stake in Dolby Laboratories Inc.

Vanguard Portfolio Management has reported a beneficial ownership of 8.24% in Dolby Laboratories Inc. common stock as of March 31, 2026.

Several BNY Mellon entities have updated their beneficial ownership filings for Dolby Laboratories, Inc. Class A Common Stock.

The Vanguard Group, Inc. has amended its Schedule 13G filing for Dolby Laboratories Inc., reporting 0% beneficial ownership due to an internal reporting realignment.